By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


Profile

SCYNEXIS Inc is drug development company which focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing lead product candidate, SCY-078 which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The SCY-078 is a novel and structurally distinct triterpenoid glucan synthase inhibitor which is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.

Contact Information

Website: www.scynexis.com
Email: investorrelations@scynexis.com
Main Phone: +1 201 884-5485
Address: 1 Evertrust Plaza
Address 2: 13th Floor
State: NJ
City / Town: Jersey City
Country: US
Postal Code: 07302 - 6548

Issuer Information

Exchange: NSD
CEO: Marco Taglietti
Employees: 38
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A